Topline data in October is the next binary catalyst. Monitor for unblinding results on the primary PET imaging endpoint and secondary clinical measures (EDSS, MFIS), which will determine the program's viability and potential partnership/licensing interest.
Price Chart
Executive Summary
Tiziana Life Sciences announced that the last patient has completed their last visit in the Phase 2a INFORM-MS trial of intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The company expects to lock the database this week and announce 12-week treatment topline data in October. This is a routine operational milestone for a clinical-stage biotech with no efficacy data released yet, making the filing neutral with low near-term price impact.
Key Facts
- Last patient completed last visit in Phase 2a INFORM-MS trial of intranasal foralumab in na-SPMS.
- Trial enrolled 48 patients across three cohorts at multiple U.S. sites.
- Primary endpoint is change in microglial activation measured by PET imaging; secondary endpoints include EDSS and MFIS.
- Database lock expected this week; topline 12-week data expected in October 2026.
- All participants eligible for a six-month open-label extension after the blinded phase.
- Expanded Access Program data showed most patients stabilized or improved over extended treatment duration.
Financial Impact
No financial data reported; pre-revenue clinical-stage biotech with no revenue or earnings disclosed.
Risk Factors
- Phase 2a topline data may fail to show statistically significant improvement on primary or secondary endpoints.
- Small sample size (48 patients) limits statistical power and generalizability.
- Open-label extension data is uncontrolled and subject to placebo effect and bias.
- Company is pre-revenue with no approved products; reliant on capital markets for funding.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-101635 |
| Document: ea030608701ex99-1.htm | 0001213900-26-101635 |
| Document: 0001213900-26-101635-index-headers.html | 0001213900-26-101635 |
| Document: 0001213900-26-101635-index.html | 0001213900-26-101635 |
| Document: 0001213900-26-101635.txt | 0001213900-26-101635 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (−11.81%) |
Oct 16, 2026 9d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (+11.81%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8907 (−15.17%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8907 (−19.76%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 | awaiting T+20 | — | $0.8907 (−9.11%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8907 (−1.54%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8907 (−22.55%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8907 (−8.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers